Pressure Bio Raises $826K in Private Placement, Gets Nasdaq Warning Letter | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has raised $825,720 in gross proceeds from a private placement, it said in a document filed on Tuesday with the US Securities and Exchange Commission.

The South Easton, Mass.-based company also disclosed that it has received a letter from Nasdaq saying its stock fails to meet a listing requirement and could face delisting action.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.